Pfizer’s mRNA Flu Vaccine Demonstrates 34.5% Superiority Over Traditional Shots in Landmark Global Trial
Pfizer's mRNA influenza vaccine outperforms traditional shots by 34.5% in a Phase…
Pfizer’s mRNA Flu Vaccine Achieves 34.5% Higher Effectiveness in Landmark Phase 3 Trial Against Traditional Shots
Pfizer's mRNA flu vaccine outperforms traditional shots by 34.5% in a major…
Pfizer mRNA Flu Vaccine Outperforms Traditional Shots by 34.5% in Pivotal Phase 3 Trial
Pfizer's mRNA influenza vaccine showed 34.5% better efficacy than traditional flu shots…
